Jane Churpek, MD, MS

Hematology, Medical Oncology and Palliative Care
Associate Professor
Clinical Science Center
600 Highland Ave
Madison WI 53792-0001


  • The Medical College of Wisconsin, Milwaukee, Wisconsin – MD
  • The University of Chicago Medical Center, Chicago, Illinois – Residency in Internal Medicine
  • The University of Chicago Medical Center – Fellowship in Hematology/Oncology
  • The University of Chicago – MS, Public Health Sciences

Professional Activities

Dr. Jane Churpek is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine. She is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Society of Human Genetics. Dr. Churpek is the recipient of an American Society for Clinical Investigation Young Physician-Scientist Award.

Clinical Specialties

Dr. Churpek is a board certified hematologist and oncologist who focuses on the care of adults with low blood counts due to acquired and inherited causes, including clonal hematopoiesis, myelodysplastic syndrome, and inherited bone marrow failure syndromes (e.g. Fanconi anemia, GATA2 deficiency syndrome, etc). She also specializes in the diagnosis and management of patients and their families with hereditary cancer predisposition syndromes such as familial leukemia syndromes, Li Fraumeni syndrome, Cowden syndrome, BAP1 syndrome and more.


View Dr. Jane Churpek’s publications on NCBI My Bibliography

Dr. Churpek’s research focuses on identifying inherited genetic factors that cause increased risk of cancer and bone marrow disorders, especially among understudied tumors and blood disorders. Her goal is to understand who is at increased risk and how specific exposures increase or decrease risk. She aims to utilize this information to optimize early detection, treatment, and, ultimately, prevention of cancer and bone marrow disorders. Dr. Churpek has contributed to the understanding of several novel hereditary blood cancer predisposition syndromes and the role of inherited predisposition in exposure associated cancers such as therapy-related leukemia and mesothelioma.